To date, more than 32,000 epilepsy patients in 24 countries have
accumulated over 100,000 patient years of experience using VNS Therapy.

abstinence bipolar

HOUSTON, Cyberonics, Inc. James W. "Years of clinical use and more than
100,000 patient years of experience have shown that VNS Therapy is a valuable
long-term treatment option for pharmacoresistant epilepsy with benefits to
patients that improve over time.

transition empowering

com/docs /NEDA_Briefing. In addition to treatment-resistant depression and pharmacoresistant
epilepsy indications , VNS Therapy is at various stages of investigational
clinical studies as a potential treatment for anxiety disorders, Alzheimer's
disease, bulimia and chronic headache/migraine.

scoliosis abstinence

Eight years after FDA approval as an
adjunctive therapy used to reduce the frequency of seizures in adults and
adolescents over 12 years of age with partial onset seizures that are
refractory to antiepileptic medications , VNS Therapy has been used to treat
more than 32,000 patients worldwide. The VNS Therapy System is also approved for sale as a treatment
for epilepsy in all the European Economic Area, Canada, Australia and other
markets.

adolesence uptake

Other
medical complications that can arise from eating disorders include
osteoporosis, kidney problems, digestive problems, heart failure,
reproductive problems and suicide.

More information can be found online at www.

adolesence puberty

Eating Disorders, although serious , are not lifestyle
choices, and are treatable."
"Global use of implants overall has doubled since the year 2000, and the
fastest growing category of implants is neurostimulators, devices used to
treat a wide range of CNS disorders, including epilepsy," notes James Cavuoto,
publisher of the Neurotech Business Report. Stimulation is delivered by the VNS Therapy System(TM), an implantable
generator similar to a cardiac pacemaker.
The VNS Therapy System was approved by the FDA on July 15, 2005 "as an
adjunctive long-term treatment for chronic or recurrent depression for
patients 18 years of age and older who are experiencing a major depressive
episode and have not had an adequate response to four or more adequate
antidepressant treatments.

teen transition

Epilepsy is the second most
prevalent neurological disorder." As part of FDA's approval order, Cyberonics is
required to conduct a 450 -patient post-market dosing study and a 1,000-
patient, five-year patient outcome registry.

transition adolesence

"Eating disorders can be silent killers that too often go unnoticed," said
Lynn Grefe, chief executive officer of NEDA."

The National Eating Disorders Association estimates that nearly 10 million
women and one million men are affected by anorexia nervosa or bulimia
nervosa, and another 25 million suffer from binge eating disorder. This case should be a wake up call to our nation to insist that
insurance companies provide adequate coverage for eating disorders as they
do other illnesses .
The 100,000 patient years milestone comes on the heels of FDA approval of
VNS Therapy as an adjunctive long-term treatment of chronic or recurrent
depression for patients 18 years of age or older who are experiencing a major
depressive episode and have not had an adequate response to four or more
adequate antidepressant treatments. The Company's initial market was epilepsy, a
disorder characterized by recurrent seizures.

concentrated bipolar

Cyberonics' VNS Therapy Surpasses 100 000 Patient Years of Experience

Wheless, Professor and Chief of
Pediatric Neurology, Le Bonheur Chair in Pediatric Neurology at the University
of Tennessee Health Science Center. was founded in 1987 to design, develop and market medical
devices for the long-term treatment of epilepsy, depression and other chronic
treatment -resistant disorders using a unique therapy, vagus nerve stimulation
(VNS).
VNS Therapy is at various levels of investigational clinical study as a
potential treatment for anxiety disorders , Alzheimer's disease, chronic
headache/migraine and bulimia.

behaviors honest

abstinence behaviors

"

According to a recent poll conducted and just released by GMI, Inc., most
Americans agree eating disorders are serious illnesses that should be
covered by insurance:

-- 76 % of respondents believe that eating disorder illnesses should be
covered by insurance like any other illness;
-- 66% of respondents believe that the government should require insurance
companies to cover treatment of eating disorders;
-- 80 % of those respondents believe that elected officials at the
state and federal level should make that happen;
-- 96 % of respondents believe eating disorders are serious illnesses;
-- 81 % of respondents believe treatment can be successful.

uptake honest

The National Eating Disorders Association today
responded to reports that the potassium deficiency which triggered Terri
Schiavo's cardiac arrest and resulted in her present condition was the
result of an eating disorder.org.

Health information , advice and support for and by teens.

teenshealth ethically

ethically bipolar

"

ABOUT VNS THERAPY AND CYBERONICS
Cyberonics , Inc.
The VNS Therapy System has been approved for sale in the European Economic
Area and in Canada as a treatment for depression in patients with treatment-
resistant or treatment-intolerant major depressive episodes, including
unipolar depression and bipolar disorder (manic depression) since 2001.

teen bipolar

Grefe continues, "Anorexia Nervosa has the highest mortality rate of any
mental illness, yet eating disorders are barely covered by medical
insurance.
Approximately 75 percent of patients reaching end of service elect to continue
with VNS Therapy, further supporting VNS Therapy 's safety and effectiveness
record.

adolescent acne

Expert neurologists, psychiatrists and
more than 1,000 surgeons from leading medical institutions around the world
are at the forefront of neuromodulation, prescribing and implanting VNS
Therapy.vnstherapy.

timely adolescents

NationalEatingDisorders. VNS Therapy is the first implantable
device-based treatment for depression and the first treatment specifically
developed, studied , approved and labeled for treatment-resistant depression.
"Approximately 30 to 40 percent of patients with epilepsy have seizures
that are not controlled by drugs alone, requiring nonpharmacologic treatment
options like VNS Therapy," said Dr."
"Once a novel treatment, today VNS Therapy is an important, safe and
effective treatment option for thousands of patients with medically refractory
epilepsy," said Eric Hargis, President and Chief Executive Officer of the
national Epilepsy Foundation . "The recent approval of VNS as a treatment for
treatment-resistant depression is also important for epilepsy patients,
considering that people with epilepsy also have a high risk of depression and
mood disorders, co-morbidities that can greatly diminish quality of life if
not adequately treated. The Company is headquartered in Houston, Texas
and has an office in Brussels, Belgium.

adolesence highlight

(Nasdaq: CYBX)
today announced that Vagus Nerve Stimulation (VNS) Therapy has accumulated
more than 100,000 patient years of experience, making it the most widely used
neurostimulation device for the treatment of epilepsy, depression and central
nervous system (CNS) disorders.

aware bipolar

Complete survey results can be found online at
http://www. "Cyberonics is clearly a market
leader in the growing neuromodulation market.

stature aware

"If a silver lining can be
found in the tragedy of Schiavo's case , it is that her situation brought to
light the serious ramifications of an eating disorder, and we can assure
you that this is not an isolated case.

honest adolescent

pdf

challenged abstinence

PRESS RELEASE Tragic Schiavo Condition Reportedly Brought on by Deadly Eating Disorder; National Eating Disorders Association Sheds Crucial Light on Silent Kil

For more information on VNS
Therapy for treatment-resistant depression, including the contraindications,
warnings and precautions, see the Physician's and Patient's Manuals and other
information at http://www.cyberonics.

behaviours highlight

The VNS Therapy System delivers
preprogrammed intermittent mild electrical pulses to the vagus nerve in the
patient's neck 24 hours a day. For additional information please
visit us at http://www.com .

abstinence highlight

com or call
1-877-NOW 4 VNS.

mahoning stature

gmipoll. The Cyberonics VNS Therapy System was
approved by the FDA on July 16, 1997 for use as an adjunctive therapy in
reducing the frequency of seizures in adults and adolescents over 12 years of
age with partial onset seizures that are refractory to antiepileptic
medications.